In recent studies conducted in in vitro and xenograft models [60], the inhibition of ATR and Chk1 demonstrated to sensitize cancer cells to TOP1 inhibitors; according to these biological evidences many trials are investigating the combination of antibodies conjugated with anti-TOP1 and Chk1 or ATR inhibitors (Table 1). The gene discussed is CHEK1; the disease is cancer.